<code id='14B12300FD'></code><style id='14B12300FD'></style>
      • <acronym id='14B12300FD'></acronym>
      <center id='14B12300FD'><center id='14B12300FD'><tfoot id='14B12300FD'></tfoot></center><abbr id='14B12300FD'><dir id='14B12300FD'><tfoot id='14B12300FD'></tfoot><noframes id='14B12300FD'>
      • <optgroup id='14B12300FD'><strike id='14B12300FD'><sup id='14B12300FD'></sup></strike><code id='14B12300FD'></code></optgroup>
        5. <b id='14B12300FD'><label id='14B12300FD'><select id='14B12300FD'><dt id='14B12300FD'><span id='14B12300FD'></span></dt></select></label></b><u id='14B12300FD'></u>
          <i id='14B12300FD'><strike id='14B12300FD'><tt id='14B12300FD'><pre id='14B12300FD'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / Wikipedia / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-10-04 11:08:40 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：367
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb
                                
                            
          Next article：  
                                      
                                          United colonoscopy coverage change 'may cost lives,' doctors say
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles